Cargando…

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma

BACKGROUND: This study examines real-world drug utilization patterns, health care resource use, and costs among patients receiving adjuvant treatment with IFN versus patients receiving no treatment (“observation”) for malignant melanoma following surgery. METHODS: A retrospective cohort study was co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Le, Trong Kim, Shaw, James W, Kotapati, Srividya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516031/ https://www.ncbi.nlm.nih.gov/pubmed/26229494 http://dx.doi.org/10.2147/CEOR.S78704

Ejemplares similares

Societal preferences for adjuvant melanoma health states: UK and Australia
por: Middleton, Mark R., et al.
Publicado: (2017)

Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
por: Hackshaw, Michelle D, et al.
Publicado: (2012)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
por: Toor, Kabirraaj, et al.
Publicado: (2021)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
por: Batteson, Rachael, et al.
Publicado: (2019)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients
por: Hribernik, Andrejc, et al.
Publicado: (2016)

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
por: Middleton, Mark R., et al.
Publicado: (2016)

Adjuvant electrochemotherapy of malignant ocular melanoma in a dog
por: dos Santos da Luz, Jean Carlos, et al.
Publicado: (2023)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human malignant melanoma
por: Mantso, T., et al.
Publicado: (2018)

Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
por: Ashraf, Farhan, et al.
Publicado: (2016)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study
por: Scott, Callie A, et al.
Publicado: (2014)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
por: Özdemir, Dilay, et al.
Publicado: (2023)

Medical resource utilization and the associated costs of asthma in China: a 1-year retrospective study
por: Yang, Xueer, et al.
Publicado: (2023)

ORAL DRUG THERAPY – IMPROVING SURVIVAL IN MALIGNANT MELANOMA
por: O’Neill, CH, et al.
Publicado: (2018)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma
por: Li, Wei, et al.
Publicado: (2017)

Malignant Melanoma: Direct Costs by Clinical and Pathological Profile
por: Buja, Alessandra, et al.
Publicado: (2022)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma
por: TREGGIARI, Elisabetta, et al.
Publicado: (2016)

Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
por: Lau, Eric, et al.
Publicado: (2015)

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
por: Federico Paly, Victoria, et al.
Publicado: (2022)

Resource Utilization and Costs of Age-Related Macular Degeneration
por: Halpern, Michael T., et al.
Publicado: (2006)

Utilization and cost of electronic resources in adult cancer center
por: Maraiki, Fatma, et al.
Publicado: (2018)

Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: A retrospective primary care database study
por: Jaggi, Ashley, et al.
Publicado: (2019)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
por: Kocaata, Zeki, et al.
Publicado: (2022)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
por: Audsley, Katherine M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pojqrlnbo94pef417vm2j5l8jj